Etude 3000 ARTHROSES Symptomatic Knee and Hip Osteoarthritis Prevalence Survey (3000ARTHROSE)

This study has been completed.
Sponsor:
Information provided by:
Central Hospital, Nancy, France
ClinicalTrials.gov Identifier:
NCT01400529
First received: July 5, 2007
Last updated: July 21, 2011
Last verified: July 2007

July 5, 2007
July 21, 2011
March 2007
November 2009   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01400529 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Etude 3000 ARTHROSES Symptomatic Knee and Hip Osteoarthritis Prevalence Survey
Etude 3000 ARTHROSES Symptomatic Knee and Hip Osteoarthritis Prevalence Survey. Programme de Recherche du Groupe Qualité de Vie, de la Section Epidémiologie et de la Section Arthrose de la Société Française de Rhumatologie

Nationwide descriptive epidemiology survey aiming to determine lower limb OA prevalence, based on a validated method previously used to assess inflammatory rheumatism (rheumatoid arthritis and spondylarthropathy) prevalence in France.

Osteoarthritis (OA) is a degenerative disease progressively affecting joint cartilage and subchondral bone, leading to pain, limited range of motion and functional impairment. Knee and hip are the more frequently affected joints. There is no treatment able to cure OA or at least to slow down cartilage damage. Thus, when symptomatic treatments become ineffective, joint prosthetic replacement is the unique solution.

There is a substantial lack of information about osteoarthritis (OA) epidemiology in France, as well as in other European countries, which becomes more and more critical with population aging. The need for additional knowledge was outlined in the law about public health priorities in France, published on August 9th, 2004. In this document, a specific call is made for additional investigation on functional limitations, disability and quality of life modification of people affected by OA.

Up to now, available information is mainly limited to short- or medium-term studies, conducted in clinic-based samples. Thus, based on demography and public health conclusions, implementing population-based epidemiologic studies is required in order to improve scientific knowledge with regards to :

  • prevalence of symptomatic OA,
  • its natural history over years and potential prognostic factors influencing the disease,
  • its impact in terms of quality of life changes, disability, lack of autonomy and health resource use.

Our expert group, which has a substantial experience in osteoarthritis, epidemiology and health service research, has developed a 2-part research program aiming to help answering to OA-related public health questions:

  • Part 1: a nationwide descriptive epidemiology survey aiming to determine lower limb OA prevalence, based on a validated method previously used to assess inflammatory rheumatism (rheumatoid arthritis and spondylarthropathy) prevalence in France.
  • Part 2: the constitution of a population-based cohort of OA patients, aiming to collect clinical, biologic and radiological data about OA natural history, predictors of structural progression, consequences on quality of life, function and health resource use.

The present study is the part 1 of the program

Observational
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Probability Sample

population based

Osteoarthritis
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
3000
November 2009
November 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • age 40-75
  • adults in households representative of the French population for age, sex, area of living and number of household members.

Exclusion Criteria:

Both
40 Months to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
France
 
NCT01400529
906297
Yes
Philippe Boulangé, direction de la recherche et de l'innovation, Central Hospital, Nancy, France
Central Hospital, Nancy, France
Not Provided
Principal Investigator: Francis Guillemin, MD, PhD Société Française de Rhumatologie
Central Hospital, Nancy, France
July 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP